RASTEZ | The Vascular Journey

The Next Era of Lipid Therapy

EZ CONTROL, ATTAIN GOAL

Silent Build-Up

Prevalence in Dyslipidemia

79.3%

A MAJOR CLINICAL CHALLENGE

“The Rule of Six” Limitations

-6% LDL-C

-6% LDL-C

-6% LDL-C

Rosuvastatin + Ezetimibe 10mg

+25%

ADDITIONAL REDUCTION IN LDL-C

RASTEZ

(Rosuvastatin + Ezetimibe)

10mg / 10mg

20mg / 10mg

Superior Potency.
Clinical Ease.